Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 3/20 | 0.58 |
| ▸ | GLS | O94925 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.49 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.49 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29419302 | 1.00 | CASP3 (0.58) | CASP3GLSALDH1A1POLBNPSR1 | |
| SCHEMBL571198 | 0.89 | CASP3 (0.54) | CASP3GLSRAB9ASMN1; SMN2TDP1 | |
| SCHEMBL6505837 | 0.87 | TDP1 (0.56) | CASP3RAB9ASMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL7451684 | 0.86 | ACHE (0.62) | CASP3GLSPOLB | |
| SCHEMBL29545568 | 0.85 | TDP1 (0.58) | CASP3TDP1L3MBTL1 | |
| SCHEMBL30601900 | 0.85 | TDP1 (0.58) | CASP3TDP1L3MBTL1 | |
| SCHEMBL997571 | 0.85 | TDP1 (0.58) | CASP3TDP1L3MBTL1 | |
| SCHEMBL606389 | 0.85 | TDP1 (0.58) | CASP3TDP1L3MBTL1 | |
| SCHEMBL793609 | 0.85 | TDP1 (0.58) | CASP3TDP1L3MBTL1 | |
| SCHEMBL31036100 | 0.85 | TDP1 (0.58) | CASP3TDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 226 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747260-A1 | MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2026-05-27 | — | — | EP | disclosed |
| EP-4737464-A2 | METAL COMPLEX AND METHOD FOR PRODUCING THE SAME, CATALYST COMPONENT FOR OLEFIN POLYMERIZATION AND CATALYST FOR OLEFIN POLYMERIZATION CONTAINING THE METAL COMPLEX, AND METHODS FOR PRODUCING ALPHA-OLEFIN POLYMER AND COPOLYMER USING THE CATALYST FOR OLEFIN POLYMERIZATION | The University Of Tokyo (JP) | 2026-05-06 | — | — | EP | disclosed |
| EP-3476858-B1 | METAL COMPLEX AND METHOD FOR PRODUCING THE SAME, CATALYST COMPONENT FOR OLEFIN POLYMERIZATION AND CATALYST FOR OLEFIN POLYMERIZATION CONTAINING THE METAL COMPLEX, AND METHODS FOR PRODUCING ALPHA-OLEFIN POLYMER AND COPOLYMER USING THE CATALYST FOR OLEFIN POLYMERIZATION | UNIV TOKYO (JP) | 2026-05-06 | — | — | EP | disclosed |
| US-12577258-B2 | Macrocyclic compound | VERNALIS (R&D) LIMITED (GB) | 2026-03-17 | — | — | US | disclosed |
| US-12370158-B2 | Analogs of CYP-eicosanoids for use in treating or preventing a disorder associated with neovascularization and/or inflammation | OMEICOS THERAPEUTICS GMBH (DE) | 2025-07-29 | — | — | US | disclosed |
| EP-4223368-B1 | MACROCYCLIC COMPOUNDS INCORPORATING PIPERIDINE AND QUINOLINE OR QUNAXOLINE AS IRAK-4 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY CONDITIONS | ASAHI KASEI PHARMA CORP (JP) | 2025-05-21 | — | — | EP | disclosed |
| WO-2025021666-A1 | MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2025-01-30 | — | — | WO | disclosed |
| CN-119367342-A | CYP-eicosanoids analogs for treating or preventing diseases associated with neovascularization and/or inflammation | 奥迈科斯治疗公司 | 2025-01-28 | — | — | CN | disclosed |
| CN-116348472-B | Macrocyclic compounds | 旭化成制药株式会社 | 2024-12-03 | — | — | CN | disclosed |
| EP-3435993-B1 | ANALOG OF CYP-EICOSANOIDS FOR USE IN TREATING OR PREVENTING A DISORDER ASSOCIATED WITH NEOVASCULARIZATION AND/OR INFLAMMATION | OMEICOS THERAPEUTICS GMBH (DE) | 2024-09-25 | — | — | EP | disclosed |
| WO-2001082978-A2 | IMAGING OF NICOTINIC ACETYLCHOLINE RECEPTOR SUBTYPES | TARGACEPT, INC. (US) | 2001-11-08 | — | — | WO | disclosed |
| WO-2001053262-A1 | ALPHA V INTEGRIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2001-07-26 | — | — | WO | disclosed |
| WO-2001053297-A1 | ALPHA V INTEGRIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2001-07-26 | — | — | WO | disclosed |
| EP-1060163-A1 | NEW PIPERAZINYL-SUBSTITUTED PYRIDYLALKANE, ALKENE AND ALKINE CARBOXAMIDES | Klinge Pharma GmbH (DE) | 2000-12-20 | — | — | EP | disclosed |
| WO-2000072801-A2 | ALPHA V INTEGRIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2000-12-07 | — | — | WO | disclosed |
| CN-1222909-A | Pyrazinone thrombin inhibitors | MERCK & CO INC (US) | 1999-07-14 | — | — | CN | disclosed |
| WO-1999031063-A1 | NEW PIPERAZINYL-SUBSTITUTED PYRIDYLALKANE, ALKENE AND ALKINE CARBOXAMIDES | KLINGE PHARMA GMBH (DE) | 1999-06-24 | — | — | WO | disclosed |
| EP-0900207-A1 | PYRAZINONE THROMBIN INHIBITORS | Merck & Co., Inc. (US) | 1999-03-10 | — | — | EP | disclosed |
| US-5866573-A | Pyrazinone thrombin inhibitors | MERCK & CO., INC. (US) | 1999-02-02 | — | — | US | disclosed |
| WO-1997040024-A1 | PYRAZINONE THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 1997-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577258-B2 | Macrocyclic compound | IRAK1, IRAK4, IRAK2 | CASP3 2119/4885GLS 3631/4885ALDH1A1 2947/4885 |
| US-12370158-B2 | Analogs of CYP-eicosanoids for use in treating or preventing a disorder associated with neovascularization and/or inflammation | ALOX5, ALOX15B, ALOX15 | CASP3 530/4885GLS 1624/4885ALDH1A1 274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.